Articles scientifiques

ARTICLES

Cancer Chronotherapy & e-Health

Komarzynski S, Huang Q, Innominato PF, Maurice M, Arbaud A, Beau J, Bouchahda M, Ulusakarya A, Beaumatin N, Breda G, Finkenstädt B, Levi F. Inter-subject differences in circadian coordination captured in real time in healthy and cancerous individual persons during their daily routine using a mobile internet platform. J Med Internet Res. 2018 Jan 5. doi: 10.2196/jmir.9779. [Epub ahead of print] PubMed PMID: 29704408.
Zhang Y, Lévi F, Chang Y. Chronotherapy with defective circadian clock? Aging (Albany NY). 2018 Apr 24;10(4):520-521. doi: 10.18632/aging.101430. PubMed PMID: 29695639.
Huang Q, Cohen D, Komarzynski S, Li XM, Innominato P, Lévi F, Finkenstädt B. Hidden Markov models for monitoring circadian rhythmicity in telemetric activity data. J R Soc Interface. 2018 Feb;15(139). pii: 20170885. doi: 10.1098/rsif.2017.0885. PubMed PMID: 29436510; PubMed Central PMCID: PMC5832732.
Ozturk N, Ozturk D, Pala-Kara Z, Kaptan E, Sancar-Bas S, Ozsoy N, Cinar S, Deniz G, Li XM, Giacchetti S, Lévi F, Okyar A. The immune system as a chronotoxicity target of the anticancer mTOR inhibitor everolimus. Chronobiol Int. 2018 Feb 5:1-14. doi: 10.1080/07420528.2018.1432632. [Epub ahead of print] PubMed PMID: 29400578.
Zhang Y, Giacchetti S, Parouchev A, Hadadi E, Li X, Dallmann R, Xandri-Monje H, Portier L, Adam R, Lévi F, Dulong S, Chang Y. Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock. Cell Cycle. 2018;17(1):33-42. doi: 10.1080/15384101.2017.1387695. Epub 2018 Jan 2. PubMed PMID: 29099263; PubMed Central PMCID: PMC5815427.
Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A. Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17. PubMed PMID: 28817838; PubMed Central PMCID: PMC5625679.
Palesh O, Haitz K, Lévi F, Bjarnason GA, Deguzman C, Alizeh I, Ulusakarya A, Packer MM, Innominato PF. Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer. Qual Life Res. 2017 Oct;26(10):2783-2791. doi: 10.1007/s11136-017-1617-2. Epub 2017 Jun 27. PubMed PMID: 28656534; PubMed Central PMCID: PMC5711611.
Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems Chronotherapeutics. Pharmacol Rev. 2017 Apr;69(2):161-199. doi: 10.1124/pr.116.013441. Review. PubMed PMID: 28351863; PubMed Central PMCID: PMC5394920.
Mteyrek A, Filipski E, Guettier C, Oklejewicz M, van der Horst GT, Okyar A, Lévi F. Critical cholangiocarcinogenesis control by cryptochrome clock genes. Int J Cancer. 2017 Jun 1;140(11):2473-2483. doi: 10.1002/ijc.30663. Epub 2017 Mar 16. PubMed PMID: 28224616.
Innominato PF, Komarzynski S, Mohammad-Djafari A, Arbaud A, Ulusakarya A, Bouchahda M, Haydar M, Bossevot-Desmaris R, Plessis V, Mocquery M, Bouchoucha D, Afshar M, Beau J, Karaboué A, Morère JF, Fursse J, Rovira Simon J, Levi F. Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project. J Med Internet Res. 2016 Nov 25;18(11):e305. PubMed PMID: 27888171; PubMed Central PMCID: PMC5148811.
Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18. PubMed PMID: 27768923.
Mteyrek A, Filipski E, Guettier C, Okyar A, Lévi F. Clock gene Per2 as a controller of liver carcinogenesis. Oncotarget. 2016 Dec 27;7(52):85832-85847. doi: 10.18632/oncotarget.11037. PubMed PMID: 27494874; PubMed Central PMCID: PMC5349878.
Bishehsari F, Levi F, Turek FW, Keshavarzian A. Circadian Rhythms in Gastrointestinal Health and Diseases. Gastroenterology. 2016 Sep;151(3):e1-5. doi: 10.1053/j.gastro.2016.07.036. Epub 2016 Jul 29. PubMed PMID: 27480174; PubMed Central PMCID: PMC5002365.
Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E. Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. Clin Pharmacokinet. 2017 Feb;56(2):165-177. doi: 10.1007/s40262-016-0431-2. PubMed PMID: 27393140.
Ortiz-Tudela E, Innominato PF, Rol MA, Lévi F, Madrid JA. Relevance of internal time and circadian robustness for cancer patients. BMC Cancer. 2016 Apr 21;16:285. doi: 10.1186/s12885-016-2319-9. PubMed PMID: 27102330; PubMed Central PMCID: PMC4839139.
Dallmann R, Okyar A, Lévi F. Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy. Trends Mol Med. 2016 May;22(5):430-445. doi: 10.1016/j.molmed.2016.03.004. Epub 2016 Apr 5. Review. PubMed PMID: 27066876.
Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International). Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016 Feb;27(2):267-74. doi: 10.1093/annonc/mdv548. Epub 2015 Nov 16. PubMed PMID: 26578731.
Natale V, Innominato PF, Boreggiani M, Tonetti L, Filardi M, Parganiha A, Fabbri M, Martoni M, Lévi F. The difference between in bed and out of bed activity as a behavioral marker of cancer patients: A comparative actigraphic study. Chronobiol Int. 2015;32(7):925-33. doi:10.3109/07420528.2015.1053909. PubMed PMID: 26158757.
Dulong S, Ballesta A, Okyar A, Lévi F. Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling. Mol Cancer Ther. 2015 Sep;14(9):2154-64. doi: 10.1158/1535-7163.MCT-15-0129. Epub 2015 Jul 3. PubMed PMID: 26141947.
Feillet C, van der Horst GT, Levi F, Rand DA, Delaunay F. Coupling between the Circadian Clock and Cell Cycle Oscillators: Implication for Healthy Cells and Malignant Growth. Front Neurol. 2015 May 11;6:96. doi: 10.3389/fneur.2015.00096. eCollection 2015. Review. PubMed PMID: 26029155; PubMed Central PMCID: PMC4426821.
Sallam H, El-Serafi AT, Filipski E, Terelius Y, Lévi F, Hassan M. The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model. Chronobiol Int. 2015 Jun;32(5):608-14. doi: 10.3109/07420528.2015.1022782. Epub 2015 May 4. PubMed PMID: 25938685.
Innominato PF, Spiegel D, Ulusakarya A, Giacchetti S, Bjarnason GA, Lévi F, Palesh O. Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. Sleep Med. 2015 Mar;16(3):391-8. doi: 10.1016/j.sleep.2014.10.022. Epub 2015 Jan 22. PubMed PMID: 25678361.
Feillet C, Krusche P, Tamanini F, Janssens RC, Downey MJ, Martin P, Teboul M, Saito S, Lévi FA, Bretschneider T, van der Horst GT, Delaunay F, Rand DA. Phase locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9828-33. doi: 10.1073/pnas.1320474111. Epub 2014 Jun 23. PubMed PMID: 24958884; PubMed Central PMCID: PMC4103330.
Lévi F, Dugué PA, Innominato P, Karaboué A, Dispersyn G, Parganiha A, Giacchetti S, Moreau T, Focan C, Waterhouse J, Spiegel D; ARTBC Chronotherapy Group. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 2014 Oct;31(8):891-900. doi: 10.3109/07420528.2014.924523. Epub 2014 Jun 13. PubMed PMID: 24927369.
Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. The circadian timing system in clinical oncology. Ann Med. 2014 Jun;46(4):191-207. doi: 10.3109/07853890.2014.916990. Review. PubMed PMID: 24915535.
Siffroi-Fernandez S, Dulong S, Li XM, Filipski E, Gréchez-Cassiau A, Peteri-Brünback B, Meijer L, Lévi F, Teboul M, Delaunay F. Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors. Cell Cycle. 2014;13(6):984-91. doi: 10.4161/cc.27868. Epub 2014 Jan 21. PubMed PMID: 24552823; PubMed Central PMCID: PMC3984321.
Ortiz-Tudela E, Iurisci I, Beau J, Karaboue A, Moreau T, Rol MA, Madrid JA, Lévi F, Innominato PF. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2014 Jun 1;134(11):2717-25. doi: 10.1002/ijc.28587. Epub 2013 Nov 25. PubMed PMID: 24510611.
Roche VP, Mohamad-Djafari A, Innominato PF, Karaboué A, Gorbach A, Lévi FA. Thoracic surface temperature rhythms as circadian biomarkers for cancer chronotherapy. Chronobiol Int. 2014 Apr;31(3):409-20. doi: 10.3109/07420528.2013.864301. Epub 2014 Jan 7. PubMed PMID: 24397341; PubMed Central PMCID: PMC4221267.
Filipski E, Berland E, Ozturk N, Guettier C, van der Horst GT, Lévi F, Okyar A. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol Appl Pharmacol. 2014 Feb 1;274(3):471-9. doi: 10.1016/j.taap.2013.12.018. Epub 2013 Dec 29. PubMed PMID: 24380837.
Li XM, Mohammad-Djafari A, Dumitru M, Dulong S, Filipski E, Siffroi-Fernandez S, Mteyrek A, Scaglione F, Guettier C, Delaunay F, Lévi F. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013 Dec 15;73(24):7176-88. doi: 10.1158/0008-5472.CAN-13-1528. Epub 2013 Oct 23. PubMed PMID: 24154875.
Costa MJ, Finkenstädt B, Roche V, Lévi F, Gould PD, Foreman J, Halliday K, Hall A, Rand DA. Inference on periodicity of circadian time series. Biostatistics. 2013 Sep;14(4):792-806. doi: 10.1093/biostatistics/kxt020. Epub 2013 Jun 6. PubMed PMID: 23743206; PubMed Central PMCID: PMC3988453.
Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Poncet A, Spiegel D, Lévi F; International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013 Jul 15;119(14):2564-73. doi: 10.1002/cncr.28072. Epub 2013 Apr 30. PubMed PMID: 23633399.
Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Lévi F. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol. 2013;(217):261-88. doi: 10.1007/978-3-642-25950-0_11. Review. PubMed PMID: 23604483.
Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F; ARTBC International Chronotherapy Group. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 2012 Dec;23(12):3110-6. doi: 10.1093/annonc/mds148. Epub 2012 Jun 27. PubMed PMID: 22745214.
Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Lévi FA. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012 Dec 1;131(11):2684-92. doi: 10.1002/ijc.27574. Epub 2012 Jul 3. PubMed PMID: 22488038.
Altinok A, Gonze D, Lévi F, Goldbeter A. An automaton model for the cell cycle. Interface Focus. 2011 Feb 6;1(1):36-47. doi: 10.1098/rsfs.2010.0009. Epub 2010 Nov 24. PubMed PMID: 22419973; PubMed Central PMCID: PMC3262245.
Lévi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv. 2011 Dec;8(12):1535-41. doi: 10.1517/17425247.2011.618184. PubMed PMID: 22097903.
Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, Levi F. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol. 2011 Sep;7(9):e1002143. doi: 10.1371/journal.pcbi.1002143. Epub 2011 Sep 8. PubMed PMID: 21931543; PubMed Central PMCID: PMC3169519.
Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C, Karaboué A, Lévi F; ARTBC International Chronotherapy Group. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011 Aug;28(7):586-600. doi: 10.3109/07420528.2011.597532. PubMed PMID: 21859417.
Bouchahda M, Lévi F, Adam R, Rougier P. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur J Cancer. 2011 Dec;47(18):2681-90. doi: 10.1016/j.ejca.2011.06.037. Epub 2011 Jul 21. Review. PubMed PMID: 21783358.
Ahowesso C, Li XM, Zampera S, Peteri-Brunbäck B, Dulong S, Beau J, Hossard V, Filipski E, Delaunay F, Claustrat B, Lévi F. Sex and dosing-time dependencies in irinotecan-induced circadian disruption. Chronobiol Int. 2011 May;28(5):458-70. doi: 10.3109/07420528.2011.569043. PubMed PMID: 21721861.
Okyar A, Piccolo E, Ahowesso C, Filipski E, Hossard V, Guettier C, La Sorda R, Tinari N, Iacobelli S, Lévi F. Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One. 2011;6(6):e20393. doi: 10.1371/journal.pone.0020393. Epub 2011 Jun 3. PubMed PMID: 21674030; PubMed Central PMCID: PMC3108586.
Scully CG, Karaboué A, Liu WM, Meyer J, Innominato PF, Chon KH, Gorbach AM, Lévi F. Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients. Interface Focus. 2011 Feb 6;1:48-60. PubMed PMID: 21544221; PubMed Central PMCID: PMC3085452.
Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol. 2011 Dec;28 Suppl 1:S253-8. doi: 10.1007/s12032-010-9716-8. Epub 2010 Nov 5. PubMed PMID: 21053102.
Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Giacchetti S, Guettier C, Azoulay D, Castaing D, Adam R. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. 2011 Mar;18(3):659-69. doi: 10.1245/s10434-010-1385-5. Epub 2010 Oct 26. PubMed PMID: 20976564; PubMed Central PMCID: PMC3044234.
Innominato PF, Palesh O, Dhabhar FS, Lévi F, Spiegel D. Regulation of circadian rhythms and hypothalamic-pituitary-adrenal axis: an overlooked interaction in cancer. Lancet Oncol. 2010 Sep;11(9):816-7. doi: 10.1016/S1470-2045(10)70171-6. PubMed PMID: 20816374.
Rajnai Z, Méhn D, Beéry E, Okyar A, Jani M, Tóth GK, Fülöp F, Lévi F, Krajcsi P. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6. doi: 10.1124/dmd.110.032805. Epub 2010 Aug 10. PubMed PMID: 20699410.
Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: Clinical implications in oncology. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):979-1001. doi: 10.1016/j.addr.2010.06.002. Epub 2010 Jun 23. Review. PubMed PMID: 20600409.
Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17. PubMed PMID: 20401611.
Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, Teboul M, Beau J, Lévi F. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 2010 Apr 15;70(8):3351-60. doi: 10.1158/0008-5472.CAN-09-4235. PubMed PMID: 20395208.
Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gorden L, Guettier C, Adam R, Lévi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9. doi: 10.1007/s00280-010-1298-9. Epub 2010 Apr 2. PubMed PMID: 20361188.
Bernard S, Cajavec Bernard B, Lévi F, Herzel H. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol. 2010 Mar 19;6(3):e1000712. doi: 10.1371/journal.pcbi.1000712. PubMed PMID: 20333244; PubMed Central PMCID: PMC2841621.
Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377-421. doi: 10.1146/annurev.pharmtox.48.113006.094626. Review. PubMed PMID: 20055686.
de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol. 2010 Apr;17(4):1010-23. doi: 10.1245/s10434-009-0887-5. Epub 2010 Jan 6. PubMed PMID: 20052553; PubMed Central PMCID: PMC2840671.
Innominato PF, Mormont MC, Rich TA, Waterhouse J, Lévi FA, Bjarnason GA. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther. 2009 Dec;8(4):361-70. Review. PubMed PMID: 20050374.
Filipski E, Lévi F. Circadian disruption in experimental cancer processes. Integr Cancer Ther. 2009 Dec;8(4):298-302. doi: 10.1177/1534735409352085. PubMed PMID: 20042408.
Wolkenhauer O, Auffray C, Baltrusch S, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JE Jr, Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, Jaster R. Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res. 2010 Jan 1;70(1):12-3. doi: 10.1158/0008-5472.CAN-09-2676. Epub 2009 Dec 22. PubMed PMID: 20028868; PubMed Central PMCID: PMC2802734.
Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, Filipski E, Tinari N, Delaunay F, Iacobelli S, Lévi F. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett. 2010 Feb 15;192(3):395-401. doi: 10.1016/j.toxlet.2009.11.017. Epub 2009 Nov 29. PubMed PMID: 19931604.
Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Lévi F. Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int. 2009 Aug;26(6):1169-88. doi: 10.3109/07420520903209942. PubMed PMID: 19731111.
Bouchahda M, Adam R, Giacchetti S, Castaing D, Brezault-Bonnet C, Hauteville D, Innominato PF, Focan C, Machover D, Lévi F. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer. 2009 Nov 1;115(21):4990-9. doi: 10.1002/cncr.24549. PubMed PMID: 19637365.
Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Lévi F, Bjarnason GA; Chronotherapy Group of the European Organization for Research and Treament of Cancer. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009 Jun 1;69(11):4700-7. doi: 10.1158/0008-5472.CAN-08-4747. PubMed PMID: 19470769; PubMed Central PMCID: PMC2690615.
Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009 Apr 10;27(11):1829-35. doi: 10.1200/JCO.2008.19.9273. Epub 2009 Mar 9. PubMed PMID: 19273699.
Altinok A, Lévi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 2009 Jan 31;36(1):20-38. doi: 10.1016/j.ejps.2008.10.024. Epub 2008 Nov 11. Review. PubMed PMID: 19041394.
Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008 Sep;25(5):680-96. doi: 10.1080/07420520802384036. PubMed PMID: 18780198.
Lévi F. [The circadian-timing system: a determinant of drug activity and a target of anticancer treatments]. Ann Pharm Fr. 2008 Jun;66(3):175-84. doi: 10.1016/j.pharma.2008.05.003. Review. French. PubMed PMID: 18706346.
Lévi F, Altinok A, Clairambault J, Goldbeter A. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos Trans A Math Phys Eng Sci. 2008 Oct 13;366(1880):3575-98. doi: 10.1098/rsta.2008.0114. Review. Erratum in: Philos Transact A Math Phys Eng Sci. 2008 Dec 28;366(1885):4665-6. PubMed PMID: 18644767.
Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F; Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008 Apr 20;26(12):2020-6. doi: 10.1200/JCO.2007.12.3117. PubMed PMID: 18421055.
Lévi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol. 2007;72:465-75. doi: 10.1101/sqb.2007.72.030. Review. PubMed PMID: 18419306.
Dulong S, Delaunay F, Lévi F. [Circadian control of muscle transcriptome]. Med Sci (Paris). 2008 Apr;24(4):372-4. doi: 10.1051/medsci/2008244372. French. PubMed PMID: 18405635.
Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J, Levi F, Rougier P. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008 Sep;67(3):255-62. doi: 10.1016/j.critrevonc.2008.02.003. Epub 2008 Apr 8. PubMed PMID: 18400508.
Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D, Castaing D. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008 Apr 1;26(10):1635-41. doi: 10.1200/JCO.2007.13.7471. PubMed PMID: 18375892.
Guillaumond F, Lacoche S, Dulong S, Grechez-Cassiau A, Filipski E, Li XM, Lévi F, Berra E, Delaunay F, Teboul M. Altered Stra13 and Dec2 circadian gene expression in hypoxic cells. Biochem Biophys Res Commun. 2008 May 16;369(4):1184-9. doi: 10.1016/j.bbrc.2008.03.009. Epub 2008 Mar 13. PubMed PMID: 18342625.

Optimisation of Post-operative Hepatic Functions

Torzilli G, Vigano L, Cimino M, Imai K, Vibert E, Donadon M, et al. Is Enhanced One-Stage Hepatectomy a Safe and Feasible Alternative to the Two-Stage Hepatectomy in the Setting of Multiple Bilobar Colorectal Liver Metastases? A Comparative Analysis between Two Pioneering Centers. Dig Surg. 2018. doi: 10.1159/000486210.
Ruiz A, Sebagh M, Wicherts DA, Castro-Benitez C, van Hillegersberg R, Paule B, et al. Long-term survival and cure model following liver resection for breast cancer metastases. Breast cancer research and treatment. 2018. doi: 10.1007/s10549-018-4714-1.
Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gomez Bravo MA, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: A study from the European Liver Transplant Registry. Transpl Int. 2018. doi: 10.1111/tri.13123.
Panisello-Rosello A, Verde E, Lopez A, Flores M, Folch-Puy E, Rolo A, et al. Cytoprotective Mechanisms in Fatty Liver Preservation against Cold Ischemia Injury: A Comparison between IGL-1 and HTK. International journal of molecular sciences. 2018;19(2). doi: 10.3390/ijms19020348.
Mohkam K, Farges O, Vibert E, Soubrane O, Adam R, Pruvot FR, et al. Risk score to predict biliary leakage after elective liver resection. Br J Surg. 2018;105(1):128-39. doi: 10.1002/bjs.10647.
Le Roy B, Gregoire E, Cosse C, Serji B, Golse N, Adam R, et al. Indocyanine Green Retention Rates at 15 min Predicted Hepatic Decompensation in a Western Population. World J Surg. 2018. doi: 10.1007/s00268-018-4464-6.
Laurenzi A, Cherqui D, Figueroa R, Adam R, Vibert E, Sa Cunha A. Totally intra-corporeal Pringle maneuver during laparoscopic liver resection. HPB (Oxford). 2018;20(2):128-31. doi: 10.1016/j.hpb.2017.05.013.
Baumann U, Adam R, Duvoux C, Mikolajczyk R, Karam V, D'Antiga L, et al. Survival of children after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2018;24(2):246-55. doi: 10.1002/lt.24994.
Zaouali MA, Panisello A, Lopez A, Castro C, Folch E, Carbonell T, et al. GSK3beta and VDAC Involvement in ER Stress and Apoptosis Modulation during Orthotopic Liver Transplantation. International journal of molecular sciences. 2017;18(3). doi: 10.3390/ijms18030591.
Saliba F, Nitta H, Younes A, Karam VH, Sobesky R, Vibert E, et al. Everolimus plus Sorafenib as a treatment option for hepatocellular carcinoma recurrence after liver transplantation. Hepatology. 2017;66:901A-2A.
Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, et al. Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results. Ann Surg Oncol. 2017;24(2):535-45. doi: 10.1245/s10434-016-5522-7.
Rajakannu M, Cherqui D, Ciacio O, Golse N, Pittau G, Allard MA, et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma. Surgery. 2017;162(4):766-74. doi: 10.1016/j.surg.2017.06.006.
Poston G, Adam R, Xu J, Byrne B, Esser R, Malik H, et al. The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. Eur J Surg Oncol. 2017. doi: 10.1016/j.ejso.2017.07.021.
Muller X, Marcon F, Sapisochin G, Marquez M, Dondero F, Rayar M, et al. Defining Benchmarks in Liver Transplantation: A Multicenter Outcome Analysis Determining Best Achievable Results. Ann Surg. 2017. doi: 10.1097/sla.0000000000002477.
Mohkam K, Farges O, Vibert E, Soubrane O, Adam R, Pruvot FR, et al. Risk score to predict biliary leakage after elective liver resection. Br J Surg. 2017. doi: 10.1002/bjs.10647.
Memeo R, de Blasi V, Adam R, Goere D, Piardi T, Lermite E, et al. Margin Status is Still an Important Prognostic Factor in Hepatectomies for Colorectal Liver Metastases: A Propensity Score Matching Analysis. World J Surg. 2017. doi: 10.1007/s00268-017-4229-7.
Linecker M, Bjornsson B, Stavrou GA, Oldhafer KJ, Lurje G, Neumann U, et al. Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity. Ann Surg. 2017;266(5):779-86. doi: 10.1097/sla.0000000000002446.
Lai Q, Feys E, Karam V, Adam R, Klempnauer J, Oliverius M, et al. Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Transplantation. 2017;101(3):555-64. doi: 10.1097/tp.0000000000001603.
Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104(5):570-9. doi: 10.1002/bjs.10447. Hosokawa I, Adam R, Allard MA, Pittau G, Vibert E, Cherqui D, et al. Outcomes of surgical shunts and transjugular intrahepatic portasystemic stent shunts for complicated portal hypertension. Br J Surg. 2017;104(4):443-51. doi: 10.1002/bjs.10431.
Golse N, Bucur PO, Ciacio O, Pittau G, Sa Cunha A, Adam R, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl. 2017;23(2):143-54. doi: 10.1002/lt.24671.
Golse N, Bucur PO, Ciacio O, Pittau G, Cunha AS, Adam R, et al. A New Definition of Sarcopenia in Patients With Cirrhosis Undergoing Liver Transplantation. Liver Transplant. 2017;23(2):143-54. doi: 10.1002/lt.24671.
Golse N, Adam R. Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results. Clinical breast cancer. 2017. doi: 10.1016/j.clbc.2016.12.012.
Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, Sa Cunha A, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transpl. 2017;23(4):440-7. doi: 10.1002/lt.24742.
Adam R, Cailliez V, Karam V. Evaluation of HTK Preservation Solutions in Liver Transplantation: A Long-Term Propensity-Based Analysis of Outcome From the European Liver Transplant Registry. Am J Transplant. 2017;17(2):585-6. doi: 10.1111/ajt.14009.
Ychou M, Rivoire M, Thezenas S, Guimbaud R, Ghiringhelli F, Mercier-Blas A, et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study-Prodige 14-ACCORD 21 (METHEP-2), a unicancer GI trial. Journal of Clinical Oncology. 2016;34(15). doi: 10.1200/JCO.2016.34.15_suppl.3512.
Yang H, Schramek D, Adam R, Levorse J, Keyes B, Wang P, et al. Dissecting chromatin dynamics in malignant progression. Cancer Research. 2016;76. doi: 10.1158/1538-7445.am2016-881.
Vigano L, Torzilli G, Cimino M, Imai K, Vibert E, Donadon M, et al. Drop-out between the two liver resections of two-stage hepatectomy. Patient selection or loss of chance? Eur J Surg Oncol. 2016;42(9):1385-93. doi: 10.1016/j.ejso.2016.03.020.
Vigano L, Cimino MM, Adam R, Torzilli G. Improving the Safety of ALPPS Procedure: The Optimal Compromise Between Dropout and Mortality Risk. Comment on Schadde E et al Prediction of Mortality After ALPPS Stage-1: An Analysis of 320 Patients From the International ALPPS Registry. Ann Surg. 2015;262: 780-786. Ann Surg. 2016. doi: 10.1097/sla.0000000000001800.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-422. doi: 10.1093/annonc/mdw235.
Torzilli G, Adam R, Vigano L, Imai K, Goransky J, Fontana A, et al. Surgery of Colorectal Liver Metastases: Pushing the Limits. Liver cancer. 2016;6(1):80-9. doi: 10.1159/000449495.
Sobesky R, Poujois A, Vanlemmens C, Hermeziu B, Adam R, Cherqui D, et al. Liver Transplantation in Severe Neurological Forms of Wilson Disease; the French Experience. Transplantation. 2016;100:S153-S.
Sobesky R, Poujois A, Brunet AS, Broussolle E, Guillaud O, Salame E, et al. LIVER TRANSPLANTATION IN SEVERE NEUROLOGICAL FORMS OF WILSON DISEASE; THE FRENCH EXPERIENCE. Journal of Hepatology. 2016;64:S153-S.
Sobesky R, Poujois A, Brunet A-S, Broussolle E, Guillaud O, Salame E, et al. Liver transplantation in severe neurological forms of Wilson disease; a multicentric French experience. Hepatology. 2016;64:73A-A.
Sebagh M, Allard MA, Bosselut N, Dao M, Vibert E, Lewin M, et al. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy. Oncotarget. 2016;7(16):21591-600. doi: 10.18632/oncotarget.7809.
Saliba F, Minczeles N, Sluijsmans I, Delvart V, Antonini T, Coilly A, et al. Renal Function at Month 1 and 6 Post-Transplant Predicts Long-Term Kidney Function and Patient Outcome. Transplantation. 2016;100:S152-S.
Saliba F, Minczeles N, Sluijsmans I, Delvart V, Antonini T, Coilly A, et al. Renal Function at Month 1 and 6 Post-Transplant Predicts Long-Term Kidney Function and Patient Outcome. Transplantation. 2016;100:S152-S.
Saliba F, Minczeles N, Sluijsmans I, Delvart V, Antonini T, Coilly A, et al. Renal Function at Month 1 and 6 Post-Transplant Predicts Long-Term Kidney Function and Patient Outcome. Transplantation. 2016;100:S152-S.
Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, et al. Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results. Ann Surg Oncol. 2016. doi: 10.1245/s10434-016-5522-7.
Rajakannu M, Awad S, Ciacio O, Pittau G, Adam R, Cunha AS, et al. Intention-to-treat analysis of percutaneous endovascular treatment of hepatic artery stenosis after orthotopic liver transplantation. Liver Transpl. 2016;22(7):923-33. doi: 10.1002/lt.24468.
Pasut G, Panisello A, Folch-Puy E, Lopez A, Castro-Benitez C, Calvo M, et al. Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury. World J Gastroenterol. 2016;22(28):6501-8. doi: 10.3748/wjg.v22.i28.6501.
Pantelis D, Huneburg R, Adam R, Holzapfel S, Gevensleben H, Nattermann J, et al. Prophylactic total gastrectomy in the management of hereditary tumor syndromes. International journal of colorectal disease. 2016;31(12):1825-33. doi: 10.1007/s00384-016-2656-9.
Panisello A, Folch-Puy E, Lopez A, Calvo M, Adam R, Rosello-Catafau J. Polyethylen-Glycol 35 Preserved Liver Graft Glycocalix and Cytoskeleton Integrity Against Cold Ischemia Reperfusion: An Approach to IGL-1 Preservation Solution. Transplantation. 2016;100:S222-S.
Olthof PB, Huiskens J, Wicherts DA, Huespe PE, Ardiles V, Robles-Campos R, et al. Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. Surgery. 2016. doi: 10.1016/j.surg.2016.10.032.
Memeo R, Laurenzi A, Pittau G, Sanchez-Cabus S, Vibert E, Adam R, et al. Repeat liver retransplantation: rationale and outcomes. Clin Transplant. 2016;30(3):312-9. doi: 10.1111/ctr.12691.
Memeo R, de Blasi V, Adam R, Goere D, Azoulay D, Ayav A, et al. Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. HPB (Oxford). 2016;18(9):781-90. doi: 10.1016/j.hpb.2016.06.004.
Mantel HT, Westerkamp AC, Adam R, Bennet WF, Seehofer D, Settmacher U, et al. Strict Selection Alone of Patients Undergoing Liver Transplantation for Hilar Cholangiocarcinoma Is Associated with Improved Survival. PLoS One. 2016;11(6):e0156127. doi: 10.1371/journal.pone.0156127.
Lai Q, Feys E, Karam V, Adam R, Klempnauer J, Oliverius M, et al. Hepatic Epithelioid Haemangio-Endothelioma and Adult Liver Transplantation: Extra-Hepatic Disease iI Not a Contraindication to Liver Transplantation. Report of the European Liver Transplant Registry Including 149 Patients. Transplantation. 2016;100:S121-S.
Lai Q, Feys E, Karam V, Adam R, Klempnauer J, Oliverius M, et al. HEPATIC EPITHELIOID HEMANGIO-ENDOTHELIOMA AND ADULT LIVER TRANSPLANTATION: PROPOSAL FOR A PROGNOSTIC SCORE BASED ON THE ANALYSIS OF THE ELTR-ELITA REGISTRY. Transplantation. 2016. doi: 10.1097/tp.0000000000001603.
Krawczyk M, Grat M, Adam R, Polak WG, Klempnauer J, Pinna A, et al. Liver Transplantation for Hepatic Trauma: A Study From the European Liver Transplant Registry. Transplantation. 2016;100(11):2372-81. doi: 10.1097/tp.0000000000001398.
Kern B, Newsome P, Karam V, Adam R, Josef F, Feurstein B, et al. Liver Transplantation for Nonalcoholic Steatohepatitise. Organ Waste or Successful Treatment of a New Epidemic? Transplantation. 2016;100:S188-S.
Karam V, Sebagh M, Rifai K, Yilmaz F, Bhangui P, Danet C, et al. Quality of life 10 years after liver transplantation: The impact of graft histology. World journal of transplantation. 2016;6(4):703-11. doi: 10.5500/wjt.v6.i4.703.
Karam V, Danet C, Samuel D, Adam R, Antonini T, Saliba F, et al. ARE THE EARLY QUALITY OF LIFE BENEFITS SUSTAINED LONG-TERM AFTER LIVER TRANSPLANTATION? A 10-YEAR LONGITUDINAL DIAGNOSIS STRATIFIED EVALUATION. Journal of Hepatology. 2016;64:S552-S3.
Karam V, Danet C, Samuel D, Adam R, Antonini T, Saliba F, et al. ARE THE EARLY QUALITY OF LIFE BENEFITS SUSTAINED LONG-TERM AFTER LIVER TRANSPLANTATION? A 10-YEAR LONGITUDINAL DIAGNOSIS STRATIFIED EVALUATION. Journal of Hepatology. 2016;64:S552-S3.
Karam V, Danet C, Samuel D, Adam R, Antonini T, Saliba F, et al. ARE THE EARLY QUALITY OF LIFE BENEFITS SUSTAINED LONG-TERM AFTER LIVER TRANSPLANTATION? A 10-YEAR LONGITUDINAL DIAGNOSIS STRATIFIED EVALUATION. Journal of Hepatology. 2016;64:S552-S3.
Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O'Grady E, Stremitzer S, et al. PARAGON II - A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016;42(12):1866-72. doi: 10.1016/j.ejso.2016.07.142.
Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, et al. Colorectal liver metastases with concomitant extrahepatic disease: Is there a hope of cure? Journal of Clinical Oncology. 2016;34(15). doi: 10.1200/JCO.2016.34.15_suppl.e15056.
Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases. Br J Surg. 2016;103(5):590-9. doi: 10.1002/bjs.10073.
Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, et al. Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors? Oncologist. 2016;21(7):887-94. doi: 10.1634/theoncologist.2015-0468.
Huneburg R, Marwitz T, van Heteren P, Weismuller TJ, Trebicka J, Adam R, et al. Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. Endoscopy international open. 2016;4(12):E1305-e10. doi: 10.1055/s-0042-112582.
Hosokawa I, Allard MA, Nitta H, Lapointe RW, Mirza D, Nuzzo G, et al. Oncological benefit of parenchyma-preserving hepatectomy for colorectal liver metastasis. Journal of Clinical Oncology. 2016;34(15). doi: 10.1200/JCO.2016.34.15_suppl.3526.
Hallet J, Sa Cunha A, Adam R, Goere D, Bachellier P, Azoulay D, et al. Factors influencing recurrence following initial hepatectomy for colorectal liver metastases. Br J Surg. 2016;103(10):1366-76. doi: 10.1002/bjs.10191.
Hallet J, Cunha AS, Adam R, Goere D, Bachellier P, Azoulay D, et al. Outcomes of Re-hepatectomy for Colorectal Liver Metastases: A Multi-Institutional Analysis. Annals of Surgical Oncology. 2016;23:S8-S.
Hallet J, Cunha AS, Adam R, Goere D, Azoulay D, Mabrut JY, et al. Outcomes of Rehepatectomy for Colorectal Liver Metastases: A Contemporary Multi-Institutional Analysis from the French Surgical Association Database. Ann Surg Oncol. 2016;23(Suppl 5):894-903. doi: 10.1245/s10434-016-5506-7.
Gitau SN, Vinayak S, Silaba M, Adam R, Shah R. High Prevalence of Liver Fibrosis in Patients with Human Immunodeficiency Virus Monoinfection and Human Immunodeficiency Virus Hepatitis-B Co-infection as Assessed by Shear Wave Elastography: Study at a Teaching Hospital in Kenya. Journal of clinical imaging science. 2016;6:22. doi: 10.4103/2156-7514.183582.
Germani G, Ferrarese A, Adam R, Karam V, O'Grady J, Mirza D, et al. INFLUENCE OF DONOR AND RECIPIENT GENDER ON LIVER TRANSPLANTATION OUTCOMES IN EUROPE: A ELTR STUDY. Digestive and Liver Disease. 2016;48:E7-E. doi: 10.1016/j.dld.2015.12.028.
Germani G, Ferrarese A, Adam R, Karam V, O'Grady J, Mirza D, et al. Influence of Donor and Recipient Gender on Liver Transplantation Outcomes in Europe: A ELTR Study. Transplantation. 2016;100:S83-S.
Germani G, Ferrarese A, Adam R, Karam V, Belli L, O'Grady J, et al. INFLUENCE OF DONOR AND RECIPIENT GENDER ON LIVER TRANSPLANTATION OUTCOMES IN EUROPE: A ELTR STUDY. Journal of Hepatology. 2016;64:S537-S8.
Folch-Puy E, Panisello A, Oliva J, Lopez A, Castro Benitez C, Adam R, et al. Relevance of Endoplasmic Reticulum Stress Cell Signaling in Liver Cold Ischemia Reperfusion Injury. International journal of molecular sciences. 2016;17(6). doi: 10.3390/ijms17060807
de'Angelis N, Pascal G, Salloum C, Lahat E, Ichai P, Saliba F, et al. Central Hepatectomy versus Extended Hepatectomy for Malignant Tumors: A Propensity Score Analysis of Postoperative Complications. World J Surg. 2016;40(11):2745-57. doi: 10.1007/s00268-016-3584-0.
Bouchahda M, Boige V, Smith D, Karaboue A, Ducreux M, Hebbar M, et al. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. Eur J Cancer. 2016;68:163-72. doi: 10.1016/j.ejca.2016.09.011.
Bejaoui M, Pantazi E, Calvo M, Folch-Puy E, Serafin A, Pasut G, et al. Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury. Oxidative medicine and cellular longevity. 2016;2016:9096549. doi: 10.1155/2016/9096549.
Bejaoui M, Panisello A, Folch-Puy E, Calvo M, Adam R, Rosello-Catafau J. Protective Effect of Intravenous High-Molecular-Weight Polyethylene Glycol on Fatty Liver Preservation. Transplantation. 2016;100:S222-S.
Bechiri MY, Eliahou L, Rouzet F, Fouret PJ, Antonini T, Samuel D, et al. Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 Years After a Domino Liver Transplantation. American Journal of Transplantation. 2016;16(7):2208-12. doi: 10.1111/ajt.13755.
Allard MA, Baillie G, Castro-Benitez C, Faron M, Blandin F, Cherqui D, et al. Prediction of the Total Liver Weight using anthropological clinical parameters: does complexity result in better accuracy? HPB (Oxford). 2016. doi: 10.1016/j.hpb.2016.11.012.
Algalarrondo V, Antonini T, Theaudin M, Chemla D, Benmalek A, Lacroix C, et al. Autonomic dysfunction and prediction of long term survival in transthyretin amyloidosis. European Heart Journal. 2016;37:569-70.
Algalarrondo V, Antonini T, Theaudin M, Chemla D, Benmalek A, Lacroix C, et al. Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. JACC-Cardiovasc Imag. 2016;9(12):1432-41. doi: 10.1016/j.jcmg.2016.07.008.
Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. American journal of human genetics. 2016;99(2):337-51. doi: 10.1016/j.ajhg.2016.06.015.
Adam R, Karam V, Cailliez V, Pratschke J, Mirza D, O'Grady J, et al. Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Propensity-Based Analysis of Outcome from the European Liver Transplant Registry. Transplantation. 2016;100:S236-S7.
Adam R, Imai K, Castro Benitez C, Allard MA, Vibert E, Sa Cunha A, et al. Outcome after associating liver partition and portal vein ligation for staged hepatectomy and conventional two-stage hepatectomy for colorectal liver metastases. Br J Surg. 2016;103(11):1521-9. doi: 10.1002/bjs.10256.
Adam R, Cailliez V, Karam V. Evaluation of HTK Preservation Solutions in Liver Transplantation: A Long-Term Propensity-Based Analysis of Outcome From the European Liver Transplant Registry. Am J Transplant. 2016. doi: 10.1111/ajt.14009.
Vigano L, Torzilli G, Cimino MM, Imai K, Costa G, Procopio F, et al. Drop-out between the two liver resections of two-stage hepatectomy for multiple bilobar colorectal metastases: Patient selection or loss of chance? Journal of Clinical Oncology. 2015;33(15).
Vibert E, Boleslawski E, Cosse C, Adam R, Castaing D, Cherqui D, et al. Arterial Lactate Concentration at the End of an Elective Hepatectomy Is an Early Predictor of the Postoperative Course and a Potential Surrogate of Intraoperative Events. Ann Surg. 2015;262(5):787-93. doi: 10.1097/sla.0000000000001468.
Truant S, Scatton O, Dokmak S, Regimbeau JM, Lucidi V, Laurent A, et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages course on morbi-mortality and implications for management. Eur J Surg Oncol. 2015;41(5):674-82. doi: 10.1016/j.ejso.2015.01.004.
Saliba F, Minczeles N, Delvart V, Antonini T, Sobesky R, Ichai P, et al. Renal function at month 1 and 6 post-transplant predicts longterm kidney function and patient outcome. Hepatology. 2015;62:821A-2A.
Ruiz A, Wicherts D, Adam R, Siesling S, Linn S, Hillegersberg R. [Resection of liver metastases in breast cancer]. Nederlands tijdschrift voor geneeskunde. 2015;159:A8453.
Ruiz A, Sebagh M, Saffroy R, Allard M-A, De La Maisonneuve PB, Bosselut N, et al. The PI3KCA mutations are frequent and remain along with recurrence of liver metastases from breast cancer in women who underwent up to 3 liver resections. Cancer Research. 2015;75(9).
Ruiz A, Castro-Benitez C, Sebagh M, Giacchetti S, Castro-Santa E, Wicherts DA, et al. Repeat Hepatectomy for Breast Cancer Liver Metastases. Ann Surg Oncol. 2015. doi: 10.1245/s10434-015-4785-8.
Rajakannu M, Magdeleinat P, Vibert E, Innominato PF, Ciacio O, Pittau G, et al. Sequential liver and lung resection for colorectal cancer metastases: In which patients should surgery be proposed? Journal of Clinical Oncology. 2015;33(15).
Mattos RO, Linhares MM, Matos D, Adam R, Bismuth H, Castaing D, et al. Risk factors associated with outcome in liver retransplantation: multicentric study. Hepatogastroenterology. 2015;62(138):341-5.
Mariani LL, Lozeron P, Theaudin M, Mincheva Z, Signate A, Ducot B, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in france. Annals of neurology. 2015. doi: 10.1002/ana.24519.
Levi FA, Boige V, Hebbar M, Smith D, Lepere C, Focan C, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2015. doi: 10.1093/annonc/mdv548.
Jones RP, Malik HZ, Fenwick SW, Gruenberger T, Stremitzer S, Rees M, et al. A single arm phase II study of neoadjuvant transarterial regional therapy (TACE) using preloaded Irinotecan Beads in patients with resectable colorectal liver metastases (CRLM). Journal of Clinical Oncology. 2015;33(15).
Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, et al. Failure to Achieve a 2-Stage Hepatectomy for Colorectal Liver Metastases: How to Prevent It? Ann Surg. 2015;262(5):772-9. doi: 10.1097/sla.0000000000001449.
Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D, et al. Two-stage hepatectomy for extensive colorectal liver metastases: How to predict the failure to complete both sequential procedures? Journal of Clinical Oncology. 2015;33(15).
Imai K, Allard MA, Benitez CC, Vibert E, Cunha AS, Cherqui D, et al. A simplified nomogram to predict long-term survival after conversion chemotherapy followed by hepatectomy for initially unresectable colorectal liver metastases. Journal of Clinical Oncology. 2015;33(15).
Hosokawa I, Ciacio O, Pittau G, Gelli M, Allard MA, Sebagh M, et al. Long-term outcome after R1 resection for colorectal liver metastases: Is a cure possible? Journal of Clinical Oncology. 2015;33(15).
Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702-8. doi: 10.1093/annonc/mdu580.
Golse N, Bucur PO, Faitot F, Bekheit M, Pittau G, Ciacio O, et al. Spontaneous Splenorenal Shunt in Liver Transplantation: Results of Left Renal Vein Ligation Versus Renoportal Anastomosis. Transplantation. 2015. doi: 10.1097/TP.0000000000000766
Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. 2015. doi: 10.1097/tp.0000000000000965.
Faitot F, Allard M-A, Pittau G, Ciacio O, Adam R, Castaing D, et al. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology. 2015;62(1):179-87. doi: 10.1002/hep.27864.
Ericzon B-G, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? Transplantation. 2015;99(9):1847-54. doi: 10.1097/tp.0000000000000574.
de Martin E, Serji B, Cherqui D, Ricca L, Adam R, Antonini TM, et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma (iCCA) or Hepatocholangiocarcinoma (HCA) on Cirrhosis: Long Term Outcome. Transplantation. 2015;99:159-60.
Bonney GK, Coldham C, Adam R, Kaiser G, Barroso E, Capussotti L, et al. Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey. J Surg Oncol. 2015;111(6):716-24. doi: 10.1002/jso.23899.
Bheeter CB, Chowdhury AD, Adam R, Jackstell R, Beller M. Efficient Rh-catalyzed C-H borylation of arene derivatives under photochemical conditions. Organic & biomolecular chemistry. 2015. doi: 10.1039/c5ob01722j.
Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, et al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes? Ann Surg. 2015. doi: 10.1097/sla.0000000000001442.
Beristain-Hernandez JL, Allard MA, Imai K, Benitez CC, Vibert E, Cunha AS, et al. Is R2 resection a valuable salvage treatment for colorectal liver metastases? Journal of Clinical Oncology. 2015;33(15).
Bejaoui M, Pantazi E, Folch-Puy E, Panisello A, Calvo M, Pasut G, et al. Protective Effect of Intravenous High Molecular Weight Polyethylene Glycol on Fatty Liver Preservation. BioMed research international. 2015;2015:794287. doi: 10.1155/2015/794287.
Bejaoui M, Pantazi E, Folch-Puy E, Baptista PM, Garcia-Gil A, Adam R, et al. Emerging concepts in liver graft preservation. World J Gastroenterol. 2015;21(2):396-407. doi: 10.3748/wjg.v21.i2.396.
Ariche A, Eshkenazy R, Adam R, d'Angelis N, Compagnon P, Salloum C, et al. Perioperative outcomes in major liver resections for colorectal liver metastasis (CRLM) in the Elderly: a case-control matched study. Journal of Clinical Oncology. 2015;33(15).
Andres A, Mentha G, Adam R, Gerstel E, Skipenko OG, Barroso E, et al. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg. 2015;102(6):691-9. doi: 10.1002/bjs.9783.
Allard MA, Sebagh M, Baillie G, Lemoine A, Dartigues P, Faitot F, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2015;22(6):1925-32. doi: 10.1245/s10434-014-4272-7.
Allard MA, Saffroy R, de la Maisonneuve PB, Ricca L, Bosselut N, Hamelin J, et al. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? Targeted oncology. 2015;10(3):415-21. doi: 10.1007/s11523-014-0346-5.
Allard MA, Cunha AS, Gayet B, Adam R, Goere D, Bachellier P, et al. Early and Long-term Oncological Outcomes After Laparoscopic Resection for Colorectal Liver Metastases: A Propensity Score-based Analysis. Ann Surg. 2015;262(5):794-802. doi: 10.1097/sla.0000000000001475.
Allard M-A, Sebagh M, Ruiz A, Guettier C, Paule B, Vibert E, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? Journal of Hepatology. 2015;63(1):83-92. doi: 10.1016/j.jhep.2015.01.023.
Algalarrondo V, Antonini T, Theaudin M, Ducot B, Lozeron P, Chemla D, et al. Prediction of Long-Term Survival After Liver Transplantation for Familial Transthyretin Amyloidosis. Journal of the American College of Cardiology. 2015;66(19):2154-6. doi: 10.1016/j.jacc.2015.08.870.
Algalarrondo V, Antonini T, Theaudin M, Ducot B, Lozeron P, Chemla D, et al. Prediction of Long-Term Survival After Liver Transplantation for Familial Transthyretin Amyloidosis. Journal of the American College of Cardiology. 2015;66(19):2154-6. doi: 10.1016/j.jacc.2015.08.870
Adani-Ife AA, Bouchahda M, Innominato PF, Karaboue A, Ulusakarya A, Haydar M, et al. Efficacy and safety of chronomodulated hepatic arterial infusion (chronoHAI) of irinotecan (I), oxaliplatin (0) and fluorouracil (F) as salvage treatment for patients (pts) with heavily pretreated liver-predominant metastatic colorectal cancer (MCC). Journal of Clinical Oncology. 2015;33(15).
Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. Journal of Hepatology. 2015;62:S170-S85.
Adam R, Karam V, Delvart V, Trunecka P, Samuel D, Bechstein WO, et al. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. American Journal of Transplantation. 2015;15(5):1267-82. doi: 10.1111/ajt.13171.
Adam R, Delvart V, Karam V, Ducerf C, Navarro F, Letoublon C, et al. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. Am J Transplant. 2015;15(2):395-406. doi: 10.1111/ajt.13060.
Adam R, Delvart V, Karam V. Reply to Letter Regarding "Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Graft Outcome Study From the European Liver Transplant Registry". Am J Transplant. 2015;15(12):3274-5. doi: 10.1111/ajt.13512.
Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer treatment reviews. 2015;41(9):729-41. doi: 10.1016/j.ctrv.2015.06.006.
Adam R, Bhangui P. Reply to letter: "resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?". Ann Surg. 2015;261(4):e109-10. doi: 10.1097/sla.0000000000000579.

Mathematical modeling for personalized cancer medicine

Stéphanou A, Fanchon E, Innominato PF, Ballesta A. Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why. Acta Biotheor. 2018 May 9. doi: 10.1007/s10441-018-9330-2. [Epub ahead of print] PubMed PMID: 29744615.
Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems Chronotherapeutics. Pharmacol Rev. 2017 Apr; 69(2):161-199. doi: 10.1124/pr.116.013441. Review. PubMed PMID: 28351863; PubMed Central PMCID: PMC5394920.
Dulong S, Ballesta A, Okyar A, Lévi F. Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling. Mol Cancer Ther. 2015 Sep;14(9):2154-64. doi: 10.1158/1535-7163.MCT-15-0129. Epub 2015 Jul 3. PubMed PMID: 26141947.
Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM. Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol. 2014 Apr 30;3:e112. doi: 10.1038/psp.2014.9. PubMed PMID: 24785551; PubMed Central PMCID: PMC4017092.
Feillet C., Krusche P., Tamanini F., Roel C, Janssens R., Downey M, Martin P., Teboul M., Saito S., Lévi F.A., Bretschneider T., van der Horst G.T.J., Delaunay F., Rand D. A. Phase-locking and multiple oscillating attractors for the coupled mammalian clock and cell cycle. Proc Natl Acad Sci U S A. 2014, 111(27): 9828-9833.
Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Lévi F. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol. 2013; (217):261-88. doi: 10.1007/978-3-642-25950-0_11. Review. PubMed PMID: 23604483.
Ballesta A, Lopez J, Popgeorgiev N, Gonzalo P, Doumic M, Gillet G. Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization. PLoS Comput Biol. 2013 Apr;9(4):e1003011. doi: 10.1371/journal.pcbi.1003011. Epub 2013 Apr 4. PubMed PMID: 23592961; PubMed Central PMCID: PMC3616992.
Ballesta A, Clairambault J. Physiologically based mathematical models to optimize therapies against metastatic colorectal cancer: a mini-review. Curr Pharm Des. 2014;20(1):37-48. Review. PubMed PMID: 23530495.
Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME. Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16. PubMed PMID: 23397042; PubMed Central PMCID:PMC3567465.
Prigent S, Ballesta A, Charles F, Lenuzza N, Gabriel P, Tine LM, Rezaei H, Doumic M. An efficient kinetic model for assemblies of amyloid fibrils and its application to polyglutamine aggregation. PLoS One. 2012;7(11):e43273. doi:10.1371/journal.pone.0043273. Epub 2012 Nov 13. PubMed PMID: 23152746; PubMed Central PMCID: PMC3496744.
Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, Levi F. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol. 2011 Sep;7(9):e1002143. doi: 10.1371/journal.pcbi.1002143. Epub 2011 Sep 8. PubMed PMID: 21931543; PubMed Central PMCID: PMC3169519.
A. Ballesta, J. Clairambault, S. Dulong, F. Lévi: Theoretical Optimization of Irinotecan-based Anticancer Strategies in case of Drug-induced Efflux, Applied Mathematics Letters, 2011 Jul ; 24 (7): 1251-1256
Bernard S., Cajavec-Bernard B., Lévi F., Herzel H. : Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput Biol., 2010, 6 (3) : e1000712.

Articles

ARTICLES

Nous contacter

Search